Genitourinary syndrome of menopause in breast cancer survivors: Are we facing new and safe hopes?

Clinical Breast Cancer

Volumn 15, Issue 6, 2015, Pages 413-420

  Biglia, Nicoletta ^a   Bounous, Valentina E ^a   Sgro, Luca G ^a   D'Alonzo, Marta ^a   Pecchio, Silvia ^a   Nappi, Rossella E ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

BCS; GSM; Iatrogenic menopause; Treatment; Vulvovaginal atrophy (VVA)

Indexed keywords

ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; FOLLITROPIN; LUBRICATING AGENT; OSPEMIFENE; PROMESTRIENE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN THERAPY; BREAST CANCER; CANCER SURVIVOR; DRUG EFFICACY; DRUG SAFETY; DYSURIA; ESTRADIOL BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; GENITOURINARY SYNDROME OF MENOPAUSE; HUMAN; HUMIDIFIER; LACTOBACILLUS; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MENOPAUSE; PELVIC ORGAN PROLAPSE; PHYSIOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; PSYCHOSOCIAL CARE; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SLEEP QUALITY; SYSTEMIC THERAPY; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINAL SECRETION; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; SURVIVOR; SYNDROME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MENOPAUSE; SURVIVORS; SYNDROME;

EID: 84947040451     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.06.005     Document Type: Review

References (91)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. American Cancer Society. Cancer Facts & Figures 2014. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed October 24, 2014.
3. C. Antoine, J. Vandromme, M. Fastrez, B. Carly, F. Liebens, and S. Rozenberg A survey among breast cancer survivors: treatment of the climacteric after breast cancer Climacteric 11 2008 322 328
4. R. Ponzone, N. Biglia, M.E. Jacomuzzi, F. Maggiorotto, L. Mariani, and P. Sismondi Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 41 2005 2673 2681
5. L. Fallowfield, D. Cella, J. Cizick, and et al. Quality of life of postmenopausal women in the "Arimidex," Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial J Clin Oncol 22 2004 4261 4271
6. J. Baumgart, K. Nilsson, A.S. Evers, T.K. Kallak, and I.S. Poromaa Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer Menopause 20 2013 162 168
7. D. Cella, L. Fallowfield, P. Barker, and et al. Quality of life of postmenopausal women in the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early stage breast cancer Breast Cancer Res Treat 100 2006 273 284
8. The North American Menopause Society (NAMS) Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause 20 2013 888 902
9. M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Sterns Practical guidelines for assessing and managing menopausal symptoms after breast cancer Ann Oncol 19 2008 1669 1680
10. D.W. Sturdee, N. Panay International Menopause Society Writing Group Recommendations for the management of postmenopausal vaginal atrophy Climacteric 13 2010 509 522
11. The North American Menopause Society (NAMS) The 2012 Hormone Therapy Position Statement of The North American Menopause Society Menopause Menopause 19 2012 257 271
12. R.E. Nappi, and M. Kokot-Kierepa Vaginal Health: Insights, Views & Attitudes (VIVA) results from an international survey Climacteric 15 2012 36 44
13. D.F. Archer Efficacy and tolerability of local estrogen therapy for urogenital atrophy Menopause 17 2010 194 203
14. C. Crandall, L. Petersen, P.A. Ganz, and et al. Association of breast cancer and its therapy with menopause-related symptoms Menopause 11 2004 519 530
15. N. Biglia, M. Cozzarella, F. Cacciari, and et al. Menopause after breast cancer: a survey on breast cancers survivors Maturitas 45 2003 29 38
16. J.A. Simon, M. Kokot-Kierepa, J. Goldstein, and R.E. Nappi Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey Menopause 20 2013 1043 1048
17. S.A. Kingsberg, S. Wysocki, L. Magnus, and M.L. Krychman Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) survey J Sex Med 10 2013 1790 1799
18. M.T. Knobf The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors Oncologist 11 2006 96 110
19. D.M. Conde, A.M. Pinto-Neto, C. Cabello, D.S. Sá, L. Costa-Paiva, and E.Z. Martinez Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer Menopause 12 2005 436 443
20. The International Menopause Society (IMS) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health Climacteric 16 2013 316 337
21. D.J. Portman, and M.L. Gass Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society Climacteric 17 2014 557 563
22. M. Rees, F.R. Pérez-López, I. Ceasu, and et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy Maturitas 73 2012 171 174
23. L. Holmberg, H. Anderson HABITS steering and data monitoring committees HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped Lancet 363 2004 453 455
24. E. Von Schoultz, L.E. Rutqvist Stockholm Breast Cancer Study Group Menopausal hormone replacement therapy after breast cancer: the Stockholm randomised trial J Natl Cancer Inst 97 2005 533 535
25. L. Holmberg, O.E. Iversen, C.M. Rudenstam, and et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors J Natl Cancer Inst 100 2008 475 482
26. M. Fahlén, T. Fornander, H. Johansson, and et al. Hormone replacement therapy after breast cancer: 10 year follow-up of the Stockholm randomised trial Eur J Cancer 49 2013 52 59
27. P. Kenemans, and L. Speroff Tibolone: clinical recommendations and practical guidelines. a report of the International Tibolone Consensus Group Maturitas 51 2005 21 28
28. P. Kenemans, N.J. Bundred, J.M. Foidart, and et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial Lancet Oncol 10 2009 135 146
29. P. Sismondi, R. Kimmig, E. Kubista, and et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients-data from LIBERATE trial Maturitas 70 2011 365 372
30. R.E. Nappi, and S.R. Davis The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI Climacteric 15 2012 267 274
31. L. Cardozo, G. Bachmann, D. McClish, and et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee Obstet Gynecol 92 1998 722 727
32. L. Mariani, A. Gadducci, E. Vizza, S. Tomao, and P. Vici Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy Gynecol Endocrinol 29 2013 25 29
33. S. Pruthi, J.A. Simon, and A.P. Early Current overview of the management of urogenital atrophy in women with breast cancer Breast J 17 2011 403 408
34. J. Suckling, R. Kennedy, A. Lethaby, and H. Roberts Local oestrogen therapy for vaginal atrophy in post menopausal women Cochrane Database Syst Rev 2006 CD001500
35. H.J. Bennink Reprint of Are all estrogens the same? Maturitas 61 2008 195 201
36. M. Diller, S. Schüler, S. Buchholz, C. Lattrich, O. Treeck, and O. Ortmann Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines Maturitas 77 2014 336 343
37. R.J. Santen, J.V. Pinkerton, M. Conaway, and et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results Menopause 9 2002 179 187
38. G. Bachmann, R.A. Lobo, R. Gut, L. Nachtigall, and M. Notelovtz Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis. A randomised controlled trial Obstet Gynecol 111 2008 67 76
39. M. Eugster-Mausmann, J. Waitzinger, and D. Lehnick Minimized estradiol absorption with ultra-low dose 10 mcg 17 b-estradiol vaginal tablets Climacteric 13 2010 219 227
40. J. Simon, L. Nachitgall, L. Ulrich, and et al. Endometrial safety of ultra-low dose estradiol vaginal tablets Obstet Gynecol 116 2010 876 883
41. R.J. Santen Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels Climacteric 17 2014 1 14
42. C. Nieto, Jl Delgado, J. Estévez, R. Usandizaga, M. De la Calle, and E. Castellanos Comparative pharmacokinetics and preliminary efficacy of two topical vaginal formulations of estriol (0.005% estriol vaginal gel, and 0.002% estriol vaginal gel) vs. the marketed reference product (Ovestinon, estriol vaginal cream 0.1%) in post-menopausal healthy volunteers Climacteric 14 suppl 1 2011 57 97
43. A. Cano, J. Estévez, R. Usandizaga, and et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study Menopause 19 2012 1130 1139
44. H. Griesser, S. Skonietzki, T. Fischer, and et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol Maturitas 71 2012 360 368
45. C.L. Loprinzi, S.L. Wolf, D.L. Barton, and N.N. Laack Symptom management in premenopausal patients with breast cancer Lancet Oncol 9 2008 993 1001
46. R.J. Santen, R.X. Song, S. Masamura, and et al. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells Adv Exp Med Biol 630 2008 19 34
47. A. Kendall, M. Dowsett, E. Folkerd, and I. Smith Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Ann Oncol 17 2006 584 587
48. E.S. O'Meara, M.A. Rossing, J.R. Daling, and et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality J Natl Cancer Inst 93 2001 754 762
49. J.E. Dew, B.G. Wren, and J.A. Eden A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer Climateric 6 2003 45 52
50. N. Biglia, E. Peano, P. Sgandurra, and et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study Gynecol Endocrinol 26 2010 404 412
51. S. Wills, A. Ravipati, P. Venuturumilli, and et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator J Oncol Pract 8 2012 144 148
52. G. Donders, P. Neven, M. Moegele, and et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study Breast Cancer Res Treat 145 2014 371 379
53. G. Pfeiler, C. Glatz, and R. Königsberg Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients Climacteric 14 2011 339 344
54. Clinicaltrials.gov [Web site]. Memorial Sloan-Kettering Cancer Center Clinical Trials. Serum estradiol levels in postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogens. Available at: https://clinicaltrials.gov/ct2/show/NCT00984399. Accessed January 08, 2015.
55. S. Buchholz, M. Mögele, A. Lintermans, and et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer Climacteric 18 2015 1 8
56. L. Del Pup, D. Postruznik, and G. Corona Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study Maturitas 72 2012 93 94
57. C. Derzko, S. Elliott, and W. Lam Management of sexual dysfunction in postmenopaual breast cancer patients taking adjiuvant aromatase inhibitor therapy Curr Oncol 14 2007 S20 S40
58. A. Sinha, and A.A. Ewies Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview Climacteric 16 2013 305 312
59. J. Carter, D. Goldfrank, and L.R. Schover Simple strategies for vaginal health promotion in cancer survivors J Sex Med 8 2011 549 559
60. C.L. Loprinzi, S. Abu-Ghazaleh, J.A. Sloan, and et al. Phase III randomised double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer J Clin Oncol 15 1997 969 973
61. Y.K. Lee, H.H. Chung, J.W. Kim, and et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial Obstet Gynecol 117 2011 922 927
62. S.L. Berga Profile of ospemifene in the breast Reprod Sci 20 2013 1130 1136
63. European Medicines Agency. Available at: www.ema.europa.eu/ema. Accessed April 24, 2015.
64. G.A. Bachmann, J.O. Komi Ospemifene Study Group Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study Menopause 17 2010 480 486
65. J. Simon, V. Lin, C. Radovich, G.A. Bachmann The Ospemifene Study Group One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus Menopause 20 2012 418 427
66. D.J. Portman, G.A. Bachmann, J.A. Simon Ospemifene Study Group Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy Menopause 20 2013 623 630
67. S.R. Goldstein, G.A. Bachmann, P.R. Koninckx, and et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy Climacteric 17 2014 173 182
68. T.L. Taras, G.T. Wurz, and M.W. DeGregorio In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer J Steroid Biochem Mol Biol 77 2001 271 279
69. R. Namba, L.J. Young, J.E. Maglione, and et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ Breast Cancer Res 7 2005 881 889
70. G.T. Wurz, K.C. Read, C. Marchisano-Karpman, and et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice J Steroid Biochem Mol Biol 97 2005 230 240
71. Q. Qu, H. Zheng, J. Dahllund, and et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats Endocrinology 141 2000 809 820
72. R.A. Burich, N.R. Mehta, G.T. Wurz, and et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model Menopause 19 2012 96 103
73. G.T. Wurz, L.H. Soe, and M.W. DeGregorio Ospemifene, vulvovaginal atrophy, and breast cancer Maturitas 74 2013 220 225
74. M. Unkila, S. Kari, E. Yatkin, and R. Lammintausta Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause J Steroid Biochem Mol Biol 138 2013 107 115
75. M. Moegele, S. Buchholz, S. Seitz, and O. Ortmann Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors Arch Gynecol Obstet 285 2012 1397 1402
76. S. Witherby, J. Johnson, L. Demers, and et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study Oncologist 16 2011 424 431
77. F. Labrie, D. Archer, C. Bouchard, and et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy Menopause 16 2009 907 922
78. D. Barton, D. Wender, J. Sloan, and et al. Randomized clinical trial to evaluate transdermal testosterone in female cancer survivors with decreased libido. North Central Cancer Treatment Group Protocol N02C3 J Natl Cancer Inst 99 2007 672 678
79. M.S. Lee Treatment of vaginal relaxation syndrome with an erbium:YAG laser using 90° and 360° scanning scopes: a pilot study and short-term results Laser Ther 23 2014 129 138
80. Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause, Published online January 20, 2015. [Epub ahead of print].
81. S. Salvatore, R.E. Nappi, N. Zerbinati, and et al. A 12-week treatment with fractional CO 2 laser for vulvovaginal atrophy: a pilot study Climateric 17 2014 363 369
82. S. Salvatore, R.E. Nappi, M. Parma, and et al. Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy Climacteric 18 2015 219 225
83. The International Menopause Society Writing Group Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health Climacteric 14 2011 302 320
84. F. Cardoso, S. Loibl, O. Pagani, and et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer Eur J Cancer 48 2012 3355 3377
85. M.L. Krychman, and A. Katz Breast cancer and sexuality: multi-modal treatment options J Sex Med 9 2012 5 13
86. J.H. Rowland, B.E. Meyerowitz, C.M. Crespi, and et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention Breast Cancer Res Treat 118 2009 99 111
87. R.E. Nappi, and S. Palacios Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause Climacteric 17 2014 3 9
88. L.R. Knoepp, S.H. Shippey, C.C. Chen, G.W. Cundiff, L.R. Derogatis, and V.L. Handa Sexual complaints, pelvic floor symptoms, and sexual distress in women over forty J Sex Med 7 2010 3675 3682
89. I.H. Braekken, M. Majida, M. Ellström Engh, and K. Bø Can pelvic floor muscle training improve sexual function in women with pelvic organ prolapse? A randomized controlled trial J Sex Med 12 2015 470 480
90. I. Juraskova, S. Jarvis, K. Mok, and et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer J Sex Med 10 2013 2549 2558
91. M.F. Goetsch, J.Y. Lim, and A.B. Caughey A solution for dyspareunia in breast cancer survivors: a randomized controlled study Obstet Gynecol 123 suppl 1 2014 1S